Advanced therapeutics for inflammatory diseases
IN INFLAMMATION RAGE MATTERS
RAGE is an important therapeutic target in a wide range of inflammatory diseases.
RAGE is a 'sensing receptor' that recognises a large number of potential triggers.
This makes it difficult to develop a drug to RAGE using traditional approaches.
At RAGE Biotech, we are harnessing cutting edge RNA-targeting and therapeutic peptide technologies to bring an effective RAGE inhibitor to the clinic.
Our aim is to improve the lives of people with chronic inflammatory conditions around the world.
MANAGEMENT
FOUNDERS
ADVISORS
"Hope lies in dreams, in imagination, and in the courage of those who dare to make dreams into reality." Jonas Salk
MEDIA & PRESS UPDATES
SUCCESSFUL COMPANY SHOWCASE WRAPS UP AT RESPIRATORY INNOVATION SUMMIT AT ATS2023 IN WASHINGTON DC
24 May, 2025
RAGE Biotech has wrapped up its participation at the American Thoracic Society ATS2023 Meeting ‘Respiratory Innovation Summit’ in Washington DC after being selected as a Featured Showcase Company. Melbourne University respiratory pharmacologist and immunologist, ATS Fellow, and RAGE’s Clinical Translation Advisor, Professor Gary Anderson spoke in Saturday morning’s panel session, ‘Showcase One: Asthma, COPD, and Airway Inflammation Innovators’.
Prof. Anderson described our Precision RNA Therapeutics for Chronic Inflammation and our therapeutic target, RAGE, a master controller of inflammation in the lung and other tissues, while our CEO Christopher Wraight met with interested investors and representatives from the pharmaceutical industry.
This May and June, RAGE Biotech is in the US, meeting with potential investors to join a Series A investment round, as our RNA medicines advance toward the clinic to help patients in need of better treatments for chronic inflammatory disease.
RAGE BIOTECH TO BE FEATURED AS SHOWCASE COMPANY AT MAJOR INTERNATIONAL MEETING
4 May, 2025
RAGE Biotech has been selected by the American Thoracic Society as a Featured Showcase Company at the ATS2023 Respiratory Innovation Summit, one of 25 companies chosen to present their innovative solutions to advancing respiratory health.
RAGE BIOTECH FOUNDERS AWARDED $1M GRANT FOR CHRONIC KIDNEY DISEASE
21 December, 2022
RAGE Biotech Founder, Chief Scientific Officer and Monash University Professor Merlin Thomas is the lead investigator on a recently announced $1M NHMRC Development Grant to investigate a novel RNA therapy targeting RAGE activation for kidney disease.
The grant-funded programme entitled ‘Splice-switching Oligonucleotides for the Treatment of Chronic Kidney Disease’ will commence in 2023 and will be administered by Monash University.
RAGE BIOTECH RECEIVES $500,000 IN ROUND ONE FUNDING FROM CUREATOR
20 July, 2022
We are very pleased to announce today that CUREator has awarded RAGE Biotech $500,000 in research support to help advance our life-changing RNA therapeutics into the clinic.
Delivered by Brandon BioCatalyst, CUREator is backed by the Australian Federal Government’s Medical Research Future Fund.
The support from CUREator brings us closer to changing the lives of patients in need of safer and more effective medicines.
MRNA VICTORIA GRANT ACCELERATES RAGE BIOTECH'S BREAKTHROUGH RNA THERAPEUTIC FOR CHRONIC LUNG DISEASE
4 July, 2022
RAGE Biotech, a pharmaceutical start-up company specialising in novel medicines for chronic inflammatory disease, has been awarded a $500,000 grant to accelerate its development of an inhaled RNA therapeutic for chronic lung inflammation.
The Company’s most advanced drug is a synthetic RNA splice-switching oligonucleotide (SSO), which the company is currently developing as an inhaled treatment, initially for COPD, with the potential to benefit more than 300 million people worldwide[1].
The mRNA Victoria Grant will support the Company’s efforts to extend the reach of its disruptive lung therapeutics technology to an even broader range of inflammatory lung disease.
mRNA Victoria is a Victorian Government initiative delivering programs to support the development and commercialisation of mRNA research. RAGE Biotech’s project ‘Accelerating the Development of an Inhaled RNA Therapeutic for the Management of Chronic Lung Disease’ is a ‘Tier 2’ programme of the mRNA Victoria Research Acceleration Fund, designed to ‘fast track’ the translation of research into health and economic outcomes.
[1] Global Burden of Disease Study 20, Lancet 386:743-800 (2015). doi:https://doi.org/10.1016/S0140-6736(15)60692-4
RAGE BIOTECH RAISES $3.7 MILLION IN SEED ROUND LED BY IP GROUP
9 November, 2021
RAGE Biotech, a university spin-out developing novel therapies to treat inflammatory diseases, has raised $3.7 million in funding to advance its breakthrough drug to clinical trials, with the potential to benefit more than 300 million people worldwide.
IP Group led the investment round, with support from Monash Investment Holdings (MIH).
The company has also announced the appointment of experienced pharmaceutical start-up leader Christopher Wraight as CEO and Director.
RAGE Biotech is commercialising inhibitors of the Receptor for Advanced Glycation End- products (RAGE), an important therapeutic target in a wide range of inflammatory diseases.
Founded on intellectual property co-developed by leading researchers from Monash University, The University of Western Australia, Murdoch University and the Baker and Perron Institutes, RAGE Biotech has world-wide exclusive technology licences to inhibitors of RAGE.
The most advanced drug is an RNA therapeutic, a splice-switching oligonucleotide (SSO), which the company is currently developing as an inhaled drug to target lung diseases where inflammation and scarring are a problem.
The breakthrough drug has the potential to improve the lives of patients globally who are suffering from chronic inflammatory lung diseases. This $3.7 million investment brings it one step closer to the clinic.
TACKLING INFLAMMATORY LUNG DISEASE
15 July, 2020
A new spin-out company will develop new therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD).
Globally, COPD is the fourth leading cause of mortality and morbidity, with chronic inflammation being a key feature and driver of disease progression in COPD, cystic fibrosis and severe asthma.
RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.
The company is founded on intellectual property co-developed by leading researchers from Monash University, The University of Western Australia, Harry Perkins Institute of Medical Research, Murdoch University and the Baker Institute, licensed to RAGE Biotech by Monash Innovation.
The breakthrough discoveries were led by endocrinology expert Professor Merlin Thomas of the Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, in collaboration with Professor Kevin Pfleger, a laboratory head at Harry Perkins Institute of Medical Research and UWA Professor and Professor Steve Wilton of Murdoch University.
AUSTRALIAN UNIVERSITIES JOIN FORCES TO TACKLE INFLAMMATORY LUNG DISEASE
8 July, 2020
A new spin-out company, RAGE Biotech, will develop novel therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD), supported by investment from IP Group, Monash University (Monash) and The University of Western Australia (UWA).
Globally, COPD is the fourth leading cause of mortality and morbidity, with chronic inflammation being a key feature and driver of disease progression in COPD, cystic fibrosis and severe asthma.
RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.
DIABETES FUNDING GROUP WELCOMES LAUNCH OF NEW BIOTECH COMPANY
8 July, 2020
WA’s peak diabetes research funding group has welcomed the creation of a new biotech company that could help fast-track fresh therapies to reduce the health complications of diabetes.
Supported by investment from IP Group, Monash University (Monash) and The University of Western Australia (UWA), the company – RAGE Biotech – is developing new approaches to modulate the Receptor for Advanced Glycation End-products (RAGE). Activation of RAGE contributes to the development of diabetes and its complications. New therapeutics blocking RAGE are therefore likely to prove significant for the prevention and treatment of diabetes.
Diabetes Research WA Executive Director Sherl Westlund welcomed RAGE Biotech’s arrival. “This is wonderful progress and very exciting given that Diabetes Research WA has channelled $60,000 into the work of UWA Professor Kevin Pfleger, who is looking at how to inhibit RAGE triggering signalling in cells that leads to inflammation and cell injury,” she said.
CONTACT US
RAGE Biotech Pty Ltd
ACN 640 194 770
Level 35, 360 Elizabeth Street
Melbourne, Victoria 3000
Australia